<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Occurrence of <z:hpo ids='HP_0000118'>phenotypic abnormalities</z:hpo> in CD34(+) hematopoietic progenitor and precursor cells (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e>) and their major B-cell and nonlymphoid compartments has been frequently reported in <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we analyze for the first time the numerical and <z:hpo ids='HP_0000118'>phenotypic abnormalities</z:hpo> of different maturation-associated subsets of bone marrow (BM) CD34(+) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e> from 50 newly diagnosed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients in comparison to <z:mpath ids='MPATH_458'>normal</z:mpath>/reactive BM (n=29) </plain></SENT>
<SENT sid="2" pm="."><plain>Our results confirm the existence of heterogeneously altered phenotypes among CD34(+) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e> from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and indicate that such variability depends both on the relative distribution of the different subsets of CD34(+) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e> committed into the different myeloid and B-lymphoid compartments, and their immunophenotype (for example, higher reactivity for CD117 and CD13 and lower expression of CyMPO, CD64 and CD65 on CD34(+) immature and neutrophil precursors), a clear association existing between the accumulation of CD34(+) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e> and that of immature CD34(+) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Interestingly, expansion of erythroid- and neutrophil-lineage CD34(+) cells is detected in low-grade <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> at the expense of CD34(+) plasmacytoid dendritic cell and B-cell precursors, while expansion of immature CD34(+) precursors occurs in high-grade <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>On the basis of the number and severity of the <z:hpo ids='HP_0000118'>phenotypic abnormalities</z:hpo> detected, a scoring system is proposed that efficiently discriminates between <z:mpath ids='MPATH_458'>normal</z:mpath>/reactive and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> CD34(+) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e>, the mean score significantly increasing from low- to high-grade <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>